According to a press statement from the firm, Pfizer was among the drugmakers most boosted by the COVID-19 epidemic, and the company has no intentions to give up its present pace in the future.

However, the information Twitter is disclosing about the corporation may alter this trend.

“Speaking this week at the J.P. Morgan Healthcare Conference in San Francisco, Pfizer CEO Albert Bourla, Ph.D., laid out scenarios that could take the drugmaker to $84 billion—or $70 billion in a less optimistic case—in non-COVID revenues in 2030,” the Pfizer release on Fierce Pharma, went on, adding:

That’d be a huge increase from 2020, when the drugmaker pulled down $41.9 billion globally. Of course, Pfizer’s trajectory changed after the company launched its massively successful COVID-19 vaccine Comirnaty and its antiviral Paxlovid.

To reach those 2030 revenue goals, the company is entering “the most important 18 months in the history of Pfizer,” Bourla said Monday. That’s because the company is planning 19 drug launches or label expansions over the next year and a half.

Those launches, in total, should generate $20 billion in sales by 2030, Bourla said. The group includes an RSV vaccine, elranatamab in multiple myeloma, ritlecitinib in alopecia areata and many other products.

Beyond those launches expected over the next 18 months, Bourla touted a pipeline of drugs expected to reach markets after the second half of 2024. Those include a much-anticipated oral GLP-1 drug, a gene therapy portfolio and several vaccines.

Here is what could derail it all.

“The latest release of the “Twitter Files” exposed actions taken by Pfizer board member and former FDA commissioner Dr. Scott Gottlieb to suppress debate over the necessity of COVID vaccines for those with natural immunity,” Western Journal reported, adding:

The findings were revealed by independent journalist Alex Berenson, a former New York Times reporter who gained recognition as a contrarian’s voice during the pandemic.

On his Substack website, “Unreported Truths,” one may access Berenson’s complete report.

Gottlieb, in his official capacity for Big Pharma, reached out to the same Twitter lobbyist that the Biden White House collaborated with to knock down a tweet from Dr. Brett Giroir, a former acting FDA commissioner who posted that the vaccination was unneeded for people with natural immunity.

In August 2021, a month before President Joe Biden issued his ill-advised and unlawful vaccination mandate, Giroir wrote: “It’s now clear #COVID19 natural immunity is superior to #vaccine immunity, by ALOT. There’s no scientific justification for #vax proof if a person had prior infection.”

Evidently, both Pfizer and Gottlieb had an intense desire to preserve the cash cow that their mRNA vaccine had become. According to Berenson, Pfizer’s mRNA vaccine provided roughly half of the company’s $81 billion in revenue in 2021. And Gottlieb was compensated $365,000 that year for his work on the Pfizer board.

Gottlieb sent an email to Todd O’Boyle, a senior official in Twitter’s public policy department, requesting that the company delete the message.

Gottlieb wrote: “This is the kind of stuff that’s corrosive. Here he draws a sweeping conclusion off a single retrospective study in Israel that hasn’t been peer reviewed. But this tweet will end up going viral and driving news coverage.”

More on this story via The Republic Brief:

O’Boyle forwarded Gottlieb’s email to the company’s strategic response team with a message that said, “Please see this report from the former FDA commissioner.” Berenson noted that O’Boyle omitted the fact that Gottlieb was a member of Pfizer’s board. CONTINUE READING…